Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks
at The Street - Wed Apr 09, 9:06AM CDT
Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.
Company news for March 31, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 9:06AM CDT
Companies in the News are: FINL,RH,CNAT,PRGS
Conatus Pharmaceuticals Reports 2013 Financial Results and Program Updates
GlobeNewswire - Thu Mar 27, 3:12PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the fourth quarter and full year ended December 31, 2013, and provided updates on its clinical development programs.
Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 20, 3:01PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2013, after the market close on Thursday, March 27, 2014. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Thursday, March 27, 2014, to discuss the financial results and provide a corporate update.
3 Reasons Potential Side Effects Trump Positive Phase 3 Data
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 17, 4:47PM CDT
In its 10-K on Friday, Intercept disclosed that patients with nonalcoholic steatohepatitis, or NASH, taking its liver drug obeticholic acid, or OCA experienced cardiovascular serious adverse events. On Sunday, the biotech followed up with...
New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus
PR Newswire - Thu Mar 13, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), GW Pharmaceuticals plc (NASDAQ: GWPH), Galena Biopharma, Inc. (NASDAQ: GALE), and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...
Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial
GlobeNewswire - Mon Mar 03, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2 clinical trial of its lead drug candidate, emricasan, in patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with inflammatory and/or fibrotic nonalcoholic steatohepatitis (NASH).
4 Big-Volume Stocks to Trade for Breakouts
at The Street - Thu Feb 27, 5:00AM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
Conatus Pharmaceuticals to Participate in Upcoming Investor Events
GlobeNewswire - Thu Feb 20, 6:00AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled participation in the following investor events in February:
Conatus Pharmaceuticals (CNAT) Soars: Stock Rises 19.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:39AM CST
Conatus Pharmaceuticals Inc. was a big mover last session, as its shares rose over 19% on the day.
Conatus Pharmaceuticals Appoints Two Additional Independent Board Members
GlobeNewswire - Mon Feb 10, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of two additional independent members to the Conatus Board of Directors: Daniel L. Kisner, M.D., a highly respected life sciences leader with demonstrated successes in drug development, pharmaceutical and research tool approvals, and venture capital investments; and Preston S. Klassen, M.D., M.H.S., an accomplished biopharmaceutical company executive with broad experience including clinical, regulatory, medical affairs and commercial responsibilities across multiple therapeutic areas.
Conatus Pharmaceuticals to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference at 1:00 p.m. ET on Monday, February 10, 2014, in New York.
Healthcare Companies Report Petition Submission, Pricing of Follow-On Offerings and Stock Price Movements - Research Report on Johnson & Johnson, GW Pharma, Conatus Pharma, Chelsea, and Insmed
PR Newswire - Tue Jan 14, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Why SodaStream, Intercept Pharmaceuticals, and lululemon athletica Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Jan 13, 7:30PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Stocks didn't deliver on their bullish promise on Monday,...
Conatus Pharmaceuticals Updates Development Strategy and 2014 Milestones
GlobeNewswire - Mon Jan 13, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced plans to initiate a placebo-controlled (open to sponsor) Phase 2b clinical trial in the second half of 2014 evaluating its lead drug candidate emricasan in Post Orthotopic Liver Transplant (POLT) recipients. The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to emricasan in late 2013 for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The trial will focus on the subset of POLT patients with reestablished liver fibrosis as a result of recurrent post-transplant hepatitis C virus infection who have successfully achieved a sustained viral response following HCV antiviral therapy (HCV-POLT).
516% Jump for Intercept Pharmaceuticals, Unknown Biotech With Unlikely Outcome
Brian Orelli, The Motley Fool - Motley Fool - Fri Jan 10, 5:00PM CST
Sometimes it takes big news to get a biotech on investors' radar. It doesn't get much bigger than the more than 500% jump that Intercept Pharmaceuticals has had over the past two days. You're excused if you've never heard of Intercept...
Intercept Pharmaceuticals Inc: A Whole New Class of Blockbuster Drug Is Born
David Williamson, The Motley Fool - Motley Fool - Thu Jan 09, 6:43PM CST
Even in the volatile world of biotech investing, the idea of a stock instantly quadrupling in value is like a unicorn -- a mythological beast that investors never expect to actually see. Well, a unicorn just showed up today, and potentially...
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 09, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Conatus Pharmaceuticals to Ring The NASDAQ Stock Market Opening Bell in Celebration of 2013 Milestones
GlobeNewswire - Wed Dec 18, 7:01AM CST
-- Live Webcast Available at 9:15 am ET --